Sale!

SCN4A Gene Hyperkalemic Periodic Paralysis Genetic Test

Name: SCN4A Gene Hyperkalemic Periodic Paralysis Genetic Test
SKU: TEST-1437
Price: 4400 AED
Availability: InStock

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The SCN4A gene hyperkalemic periodic paralysis genetic test is a specialized diagnostic procedure aimed at identifying mutations in the SCN4A gene, which are associated with hyperkalemic periodic paralysis (HyperPP). HyperPP is a rare genetic disorder characterized by episodes of muscle weakness or paralysis, often triggered by elevated potassium levels in the blood. The condition is inherited in an autosomal dominant manner, meaning a mutation in just one of the two copies of the gene can cause the disorder.

This test is crucial for individuals who exhibit symptoms of HyperPP or have a family history of the condition, as it can provide a definitive diagnosis. Early identification of the disorder is vital for managing symptoms, preventing potential complications, and making informed decisions about family planning.

The test is available at DNA Labs UAE, a reputable facility known for its advanced genetic testing services. The cost of the SCN4A gene hyperkalemic periodic paralysis genetic test is 4400 AED. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the SCN4A gene.

Upon completion, the results can offer critical insights into the genetic underpinnings of the individual’s condition, enabling personalized treatment plans and lifestyle adjustments to better manage the symptoms of hyperkalemic periodic paralysis.

Description

SCN4A Gene Hyperkalemic periodic paralysis Genetic Test

Test Name: SCN4A Gene Hyperkalemic periodic paralysis Genetic Test

Components: Blood or Extracted DNA or One drop Blood on FTA Card

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for SCN4A Gene Hyperkalemic periodic paralysis NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SCN4A Gene Hyperkalemic periodic paralysis.

Test Details:

The SCN4A gene is responsible for producing a protein called the sodium channel alpha subunit 4, which is involved in the functioning of sodium channels in muscle cells. Mutations in the SCN4A gene can lead to a condition called hyperkalemic periodic paralysis (HYPP).

Hyperkalemic periodic paralysis is a rare genetic disorder characterized by episodes of muscle weakness or paralysis. These episodes are often triggered by factors such as stress, exercise, or high-potassium foods. During an episode, the affected individual may experience muscle stiffness, weakness, or even complete paralysis. These episodes can last from minutes to hours and typically resolve spontaneously.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the simultaneous analysis of multiple genes. In the case of hyperkalemic periodic paralysis, NGS can be used to sequence the SCN4A gene and identify any mutations or variations that may be present.

NGS genetic testing for hyperkalemic periodic paralysis can help confirm a diagnosis, especially in individuals with atypical or milder symptoms. It can also be used for genetic counseling and family planning purposes. Additionally, NGS testing may provide insights into the specific mutation present in an individual, which can help guide treatment decisions and management strategies.

It is important to note that NGS genetic testing should be performed and interpreted by qualified healthcare professionals, such as geneticists or genetic counselors, who can provide appropriate guidance and support based on the results.

Test Name	SCN4A Gene Hyperkalemic periodic paralysis Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Neurological Disorders
Doctor	Neurologist
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for SCN4A Gene Hyperkalemic periodic paralysis NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with SCN4A Gene Hyperkalemic periodic paralysis
Test Details	The SCN4A gene is responsible for producing a protein called the sodium channel alpha subunit 4, which is involved in the functioning of sodium channels in muscle cells. Mutations in the SCN4A gene can lead to a condition called hyperkalemic periodic paralysis (HYPP). Hyperkalemic periodic paralysis is a rare genetic disorder characterized by episodes of muscle weakness or paralysis. These episodes are often triggered by factors such as stress, exercise, or high-potassium foods. During an episode, the affected individual may experience muscle stiffness, weakness, or even complete paralysis. These episodes can last from minutes to hours and typically resolve spontaneously. NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the simultaneous analysis of multiple genes. In the case of hyperkalemic periodic paralysis, NGS can be used to sequence the SCN4A gene and identify any mutations or variations that may be present. NGS genetic testing for hyperkalemic periodic paralysis can help confirm a diagnosis, especially in individuals with atypical or milder symptoms. It can also be used for genetic counseling and family planning purposes. Additionally, NGS testing may provide insights into the specific mutation present in an individual, which can help guide treatment decisions and management strategies. It is important to note that NGS genetic testing should be performed and interpreted by qualified healthcare professionals, such as geneticists or genetic counselors, who can provide appropriate guidance and support based on the results.